UTILIZATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL (PBPK) TO STUDY THE INFLUENCE OF BODY FAT MASS AND INDUCTION OF CYP1A2 ON THE PHARMACOKINETICS OF TCDD

by | Aug 8, 2018